|1.||Gastroesophageal Reflux (GERD)
|3.||Acquired Immunodeficiency Syndrome (AIDS)
|4.||Pathologic Constriction (Stenosis)
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
|1.||Komaki, Ritsuko: 14 articles (12/2014 - 06/2003)|
|2.||Liao, Zhongxing: 10 articles (12/2014 - 05/2005)|
|3.||Harnett, Karen M: 10 articles (09/2011 - 12/2004)|
|4.||Biancani, Piero: 10 articles (09/2011 - 12/2004)|
|5.||Li, Yan: 10 articles (06/2011 - 11/2005)|
|6.||Werner-Wasik, Maria: 9 articles (10/2014 - 01/2002)|
|7.||Martin, Robert C G: 9 articles (06/2011 - 11/2005)|
|8.||Tolia, Vasundhara: 8 articles (07/2015 - 01/2002)|
|9.||Cox, James D: 8 articles (09/2013 - 05/2005)|
|10.||Behar, Jose: 8 articles (09/2011 - 04/2005)|
|1.||Omeprazole (Esomeprazole)FDA LinkGeneric
09/01/1997 - "This study indicates that omeprazole is highly effective for all grades of esophagitis in the intellectually disabled. "
01/01/2010 - "In conclusion, omeprazole given at a dose ranging from 0.3 to 3.5 mg/kg once daily (median 1 mg/kg once daily) for at least 12 weeks is highly effective in childhood esophagitis."
11/01/1998 - "Omeprazole is highly effective for all grades of esophagitis in intellectually disabled children, without adverse effects. "
07/01/1993 - "We found omeprazole to be highly effective in this group of patients with severe esophagitis refractory to other measures. "
05/27/1992 - "The acid suppressant omeprazole, highly effective in erosive esophagitis, is the drug of choice for esophagitis resistant to H2-receptor antagonists. "
|2.||lansoprazole (Prevacid)FDA LinkGeneric
08/01/2009 - "One hundred ninety-five subjects received lansoprazole for <1 to 72 months; most received daily doses of <or=30 mg. Lansoprazole maintained erosive esophagitis remission in 75% of subjects receiving treatment for <or=72 months, with 39 subjects experiencing 50 recurrences. "
03/01/2005 - "Lansoprazole produced a significant reduction from baseline in the median percentage of days with reflux symptoms (91 to 43% in the 64 adolescents with non-erosive disease and 85 to 16% in the 23 adolescents with erosive esophagitis, P < or = 0.001 for each comparison). "
06/01/2002 - "Both regimens significantly reduced esophageal acid exposure time and increased the median 24-h gastric pH. Both long term lansoprazole regimens are equally effective in preventing the recurrence of esophagitis, independent of the modality of drug administration. "
08/01/2009 - "Long-term lansoprazole is effective and well tolerated when used to maintain erosive esophagitis remission for <or=6 years."
03/01/2005 - "Lansoprazole 30 mg once daily for 8 weeks was effective in healing erosive esophagitis. "
|3.||Proton Pump InhibitorsIBA
01/01/2001 - "In patients with moderate or severe esophagitis, proton pump inhibitors are the mainstay of treatment and the most effective in preventing symptoms and esophagitis. "
09/01/1997 - "In these patients with endoscopic evidence of damaged esophageal mucosa, both proton pump inhibitors were highly effective and safe in acute healing of erosive esophagitis and were significantly better than H2 receptor antagonists, healing faster and much more completely, with shorter durations of treatment. "
09/01/2009 - "Although proton pump inhibitors (PPIs) are very effective in the treatment of esophagitis, a significant proportion of patients have persistent symptoms even during high dosing of PPIs. "
01/01/1998 - "Therapy with more potent acid-suppressive agents such as proton pump inhibitors (PPIs) may lead to improved symptomatic relief and to superior healing compared with H2RA therapy, especially in those patients with more advanced erosive esophagitis. "
07/14/2005 - "Proton pump inhibitors given at the recommended dose are equally effective for healing esophagitis."
|4.||Ranitidine (Zantac)FDA LinkGeneric
06/01/1983 - "Both drugs proved significantly effective in inducing symptomatic and endoscopic improvement, but Ranitidine appeared significantly superior in promoting disappearance or improvement of endoscopic esophagitis. "
06/01/1987 - "The esophagitis, as judged by all observers, improved more in the ranitidine group than in the placebo group, but the difference did not reach statistical significance."
04/01/1993 - "We conclude that ranitidine 150 mg or 300 mg administered four times daily is effective for healing erosive esophagitis and relieving its symptoms."
12/01/1989 - "Treatment with ranitidine 150 mg per os twice a day for 12 weeks improved esophagitis in all patients, but the voice improved in only one of the two patients with completely healed esophagitis. "
04/01/1993 - "Two ranitidine dosages were compared for the treatment of erosive esophagitis in a multicenter, double-blind, randomized, parallel-group, placebo-controlled study. "
|5.||Sucralfate (Carafate)FDA LinkGeneric
04/01/1997 - "Sucralfate, prokinetic agents, and H2-receptor antagonists promote symptom relief and esophageal healing in mild esophagitis, but are less effective in the treatment of moderate to severe esophagitis. "
09/28/1987 - "Endoscopy showed improvement in 53 percent of patients and healing of esophagitis in 31 percent after sucralfate treatment. "
08/01/1987 - "Endoscopy showed improvement of esophagitis in 53% and healing in 31% of patients after sucralfate treatment. "
03/01/1997 - "Placebo-controlled trial of sucralfate for inhibiting radiation-induced esophagitis."
03/01/2010 - "The efficiency of sucralfate in corrosive esophagitis: a randomized, prospective study."
|6.||pantoprazole (Protonix)FDA LinkGeneric
11/01/2000 - "Pantoprazole was safe and effective for healing erosive esophagitis and provided rapid symptomatic relief. "
01/01/2013 - "Pantoprazole is effective in relieving upper and lower gastro-intestinal symptoms overlapping with erosive esophagitis, and provides sustained improvement in HRQoL post-treatment. "
01/01/2010 - "Pantoprazole been shown to improve acid reflux-related symptoms, heal esophagitis, and improve health-related quality of life more effectively than histamine-2 receptor antagonists. "
09/01/2010 - "Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis."
06/01/2008 - "It is safe to give pantoprazole intravenously and continuously for treatment of severe erosive esophagitis."
|7.||Proton Pumps (Proton Pump)IBA
01/01/1997 - "Endoscopic verification is not necessary in patients with non-severe esophagitis who have been clinically improved by an initial treatment by H2 blockers or proton pump inhibitor, even among patients with confluent esophageal erosions."
06/01/1989 - "Early results using parietal cell proton-pump blocking agents suggest that they may be effective in the treatment of severe esophagitis previously resistant to medical therapy. "
11/07/2012 - "Efficacy of endoluminal gastroplication in Japanese patients with proton pump inhibitor-resistant, non-erosive esophagitis."
03/01/2011 - "Esophagitis and esophageal acid exposure at 3 months and reflux symptoms, proton-pump inhibitor use, and quality of life at 5 years improved similarly. "
11/01/2014 - "Secondary outcomes were proton pump inhibitor (PPI) use, degree of esophagitis, safety, and changes in esophageal acid exposure. "
|8.||Cimetidine (Biomet)FDA LinkGeneric
10/01/1980 - "In an eight-week double-blind trial, the effectiveness of cimetidine (1.6 g/day) was compared to placebo in 34 patients with symptomatic esophagitis confirmed by endoscopy with biopsies and/or by acid infusion test. "
04/21/1979 - "In only 4 of 16 cimetidine patients there was complete healing of esophagitis at the end of the study. "
04/01/1986 - "Although esophagitis readily resolved with cimetidine therapy, ulceration was generally resistant to medical therapy. "
03/01/1986 - "Cimetidine in a dose of 800 or 1600 mg daily resulted in a significant symptomatic improvement and a decrease in the extent of endoscopic esophagitis. "
11/01/1985 - "In a Canadian multicenter trial, a new dosing regimen of cimetidine (Tagamet)-600 mg given twice a day-was compared with the standard regimen of 300 mg four times a day in 118 evaluable patients with endoscopically proved esophagitis. "
|9.||Amifostine (Ethyol)FDA LinkGeneric
01/01/2002 - "The purpose of these 2 clinical trials was to investigate whether daily pretreatment with amifostine could reduce the incidence of esophagitis, and acute and late lung toxicity without affecting the antitumor efficacy of the treatment. "
05/01/2003 - "Pretreatment with amifostine showed a trend toward reducing the severity of esophagitis associated with concurrent chemoradiotherapy, but it did not reach statistical significance. "
06/01/2013 - "We report the long-term results of RTOG 9801, a randomized trial investigating the ability of amifostine, a radioprotector, to reduce chemoradiation-induced esophagitis. "
10/01/2008 - "Grade 3 esophagitis was reported in 30% of patients treated with amifostine and 9% of patients treated with epoetin-alpha (P = .059). "
01/01/2008 - "Twenty-four patients were enrolled: 18 patients were enrolled initially; 6 additional patients were enrolled following a protocol amendment designed to reduce the esophagitis by adding the radioprotectant amifostine. "
|10.||Fluconazole (Zonal)FDA LinkGeneric
02/01/1994 - "Overall, the data of this study suggest a beneficial effect of prophylactic maintenance therapy with fluconazole against Candida esophagitis, particularly in the population with > 100 CD4+/microliters. "
06/01/1999 - "Candidal esophagitis showed a biphasic pattern, the second peak probably due to the emergence of fluconazole resistance. "
12/01/1996 - "Itraconazole+flucytosine association may represent an alternative therapeutic regimen for patients with fluconazole-resistant Candida esophagitis."
02/01/1994 - "After resolution of this initial esophagitis, all subjects were given fluconazole, 100 mg/die, and followed up for a 6 month period. "
05/10/1993 - "We report a case of fluconazole-resistant C albicans esophagitis that developed after fluconazole was used for more than 600 days."
12/01/1996 - "More than 90% of the patients in this series were symptomatically improved, and 92% of those studied endoscopically had healed esophagitis and intact fundoplication. "
07/01/1991 - "Four children were symptomatic without improvement in spite of medical therapy and two others required fundoplication for continued severe symptoms and refractory esophagitis. "
01/01/2011 - "The above results show efficacy of fundoplication as a method of esophagitis prevention. "
07/01/1999 - "The aim of this study was to compare the utilization of health care resources and long term outcome of erosive esophagitis in patients treated with and without open Nissen fundoplication. "
02/01/1997 - "This study was performed to determine whether the degree of esophagitis preoperatively influences the clinical outcome after laparoscopic Nissen fundoplication. "
07/01/2015 - "Radiation esophagitis is one of the commonest complications of the radiotherapy involving esophagus. "
06/01/2015 - "These results suggest that rs17788084 genetic variation in SDC2 is associated with risk of radiation esophagitis and might serve as a potential biomarker for personalized radiotherapy of ESCC."
06/01/2015 - "Eleven functional haplotype-tagging single nucleotide polymorphisms (htSNPs) of SDC2 were genotyped in 296 ESCC patients who received radiotherapy alone, and had different response and esophagitis. "
03/01/2015 - "Acute radiation-induced esophagitis (ARIE) is one of main toxicities complicated by thoracic radiotherapy, influencing patients' quality of life and radiotherapy proceeding seriously. "
01/01/2015 - "Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid)."
|3.||Transplantation (Transplant Recipients)
07/01/2012 - "However, the prevalence of endoscopic erosive esophagitis (EE) and associated risk factors after transplantation are unknown. "
09/01/1999 - "Patient no. 1 had primary CMV disease with biopsy-proven CMV esophagitis 2 months after transplantation. "
01/01/1989 - "T-cell populations in liver and renal transplant recipients with infectious esophagitis."
02/01/1988 - "Candida esophagitis occurred within 6 months after transplantation, and only one patient had recurrence. "
05/01/1985 - "We reviewed all cases of infectious esophagitis diagnosed after marrow transplantation during a 2-yr period. "
01/01/1997 - "[Evaluation by a randomized trial of the usefulness of endoscopy after treatment of a flare-up of non-severe esophagitis]."
06/01/2004 - "Both before and after treatment they displayed statistically significant differences between the esophagitis and non-esophagitis groups. "
02/01/2003 - "Esophagitis was assessed at baseline and after treatment by visual inspection and by the histology of biopsies from the distal third of the esophagus. "
02/01/2003 - "The intensity of 5 common symptoms of esophagitis was scored before and after treatment on a 4-point scale. "
01/01/1995 - "After treatment, relapse is seen in a majority of cases in whom esophagitis is present at start of therapy. "
|5.||Drug Therapy (Chemotherapy)
04/01/2012 - "Multivariate statistical model building with cross-validation suggests that a two-variable logistic model based on mean dose and the use of concurrent chemotherapy robustly predicts acute esophagitis risk in combined-data WUSTL and RTOG 93-11 trial datasets."
07/15/2015 - "A Contralateral Esophagus-Sparing Technique to Limit Severe Esophagitis Associated With Concurrent High-Dose Radiation and Chemotherapy in Patients With Thoracic Malignancies."
01/01/2014 - "Maximum esophageal dose (p = 0.029), concurrent chemotherapy (p = 0.022) and esophageal FDG PET NSUV ratio (during-RT to baseline, p = 0.007), were independent factors associated with esophagitis and area under curves (AUC) were 0.76, 0.70 and 0.78, respectively. "
12/01/2013 - "Our understanding of these mechanisms and of the pharmacotherapy of esophagitis is still evolving. "
12/01/2013 - "Esophagitis in children: an update on current pharmacotherapy."